LOS ANGELES--(BUSINESS WIRE)--Global Coalition for Adaptive Research, the U.S. Sponsor of REMAP-COVID, announced that Eisai has ended the evaluation of eritoran in the REMAP-COVID study. Eritoran, an investigational TLR-4 antagonist discovered and developed by Eisai, was selected for evaluation because it was hypothesized to suppress the over-production and release of various pro-inflammatory mediators (“cytokine storm”) observed in some COVID-19 patients by modulating the production of inflammatory cytokines. The decision to terminate the evaluation was due to changes in the COVID-19 landscape.
Eisai, in alliance with the Global Coalition for Adaptive Research (GCAR) and University of Pittsburgh Medical Center (UPMC), is set to join the REMAP-COVID study designed to assess various treatments for Covid-19.
Market Place
Share
Share
